1 Transmission of Antiretroviral Drug Resistance and Potential Impact on Selection of First-Line Therapy Mark A. Wainberg McGill University AIDS Centre Jewish General Hospital Montreal, Canada
2 Lessons from ACTG 5142
3 Riddler S. THLB 0204 ACTG 5142 : EFV vs LPV/r chez le patient naïf Etude ouverte, multicentrique, randomisé chez des patients naïfs Patients naïfs CV > 2000cpm Tx de CD4 indifférent LPV/r SGC 533/133 mg BID + EFV 600 mg QD LPV/r SGC 400/100 mg BID + 2 NRTI EFV 600 mg QD + 2 NRTI 96 semaines 3TC + TDF ou d4t XR ou ZDV (choix investigateur) Stratification : CV > 5log; co-infection hépatique, sélection NRTI Significativité statistique = 0,016 après ajustement sur : la comparaison des bras 2 à 2 les deux co-objectifs principaux analyse intermédiaire
4 ACTG 5142 : résultats (1) Objectif primaire : comparer les bras deux à deux : -le délai avant l échec virologique -précoce (Δ CV < 1 log ou rebond avant S32) -tardif (CV non < 200 cpm ou rebond après S32) -Arrêt de ttt pour échec virologique ou EI. Caractéristiques BL : LPV/EFV n = 250 LPV n = 253 EFV n = 250 Total n = 753 Female (%) Non-White (%) Age (median) CD4 (median) HIV RNA >10 3 (%) Selected NRTI (%) ZDV d4t XR TDF Riddler S. THLB 0204
6 Conclusion NNRTIs have a very low genetic barrier for resistance. LPV/r has a very high genetic barrier for resistance
7 Other evidence in support of the low genetic barrier for resistance for NNRTIs: 1. Development of the K103N mutation after single-dose use of NVP in MTCT studies. 2. Evidence for development of K103N and other NNRTI mutations after treatment interruption. This results in compromise regarding future use of NNRTIs.
8 3. Patients to whom NNRTI mutations have been transmitted have diminished responsiveness to NNRTIs that are employed in subsequent therapy. 4. Patients who have NNRTI mutations detected by ultrasensitive assays rather than genotyping may be more likely to fully express such mutations when NNRTI therapy is introduced.
9 Baseline Samples with Detectable Minority Mutations and Treatment Outcomes Sample ID Baseline Minority Mutations Regimen Outcome Treatment Week of Failure Bulk Genotype Mutations at Failure 1 M184V ABC -3TC+EFV Failure 48 Unk 2 M184V ABC -3TC+EFV Failure 12 M184V 3 K103N ABC -3TC+EFV Failure 8 K103N, M184V 4 K103N, M148V ABC -3TC+EFV Failure 8 K103N, M184V 5 K103N ZDV+3TC+EFV Failure 24 K103N 6 K103N ZDV+3TC+EFV Failure 48 Unk 7 Y181C ABC -3TC+EFV Failure 12 WT 8 Y181C ABC -3TC+EFV Success 9 K103N ABC -3TC+EFV Success NA NA Johnson et al., PLos Medicine :e158.
10 Fraction of Treatment Success or Failure Versus Presence of Detectable Minority Drug Resistance Mutations Mutation Status Treatment Success (n = 221) Treatment Failure (n = 95) No detectable drug Resistance mutation 219 (99.1%) 88 (92.6%) Minority drug Resistance mutation 2 (0.9%) 7 (7.4%) Johnson et al., PLos Medicine :e158.
11 Prevalence (%) Differential Presence of Select Drug Resistance Mutations in Patient Populations TAMs NNMs M184V PRAMs Long-term treated patients (n=380) PHI (Untreated n=59)
12 Minority Drug-Resistant Populations in Primary Infection (n=30) Number positive by sequence-based genotyping Number positive by allele-specific PCR Presence of K103N 0 3 Presence of M184V 0 4
13 Population-based surveillance shows transmission cascades of HIV-1 variants harbouring drug resistance
14 Pol gene sufficient to reconstruct transmission events RT and protease sequences are conserved A single dominant viral species is transmitted & persists Sequence clustering infers viral interrelationships Hué S, AIDS 2004
15 Clustering of PHI transmission events Brenner B, et al, JID April, 2007
17 Drug resistance in clustered and nonclustered PHI, in relation to CI potential transmitters Drug class CI - Treated PHI Cluster PHI Unique P values Any NRTI 64.4% 3.8% 9.0% Any NNRTI 37.8% 10.2% 9.0% n.s Any PI 42.2% 2.4% 5.0% 0.092
18 Nombre des cas Age distribution of PHI in clustered and unique transmissions 60 CLUSTERS UNIQUE Age
19 % of Cases (n=518 cases) The potential impact of rapid testing in HIV-1 prevention Disease stage at diagnosis ( ) Time from last reported HIV negative test at diagnosis 40 Non-specific illness AIDS defining illness Chronic symptomatic Recent / asymptomatic Acute % of cases ( , n= 1484) Duration from last known HIV negative test (yrs)
20 Global distribution of HIV-1 subtypes 1.3 million 2 million 4.8 million URF 4.2% AE 3.1% G 5% D 3.6%
21 [TDF] ( M) Rapid Selection of K65R Resistance in Subtype C Isolates 20 K65R wt (wk 34-78) Subtype C Subtype B Week
22 History of 23 Botswana Patients Treated with ddi/d4t plus 3TC or NVP No. Patients 23 No. Patients failing 15 No. Patients with K65R 7 No. Patients with L74V 0
23 Do We Need to Worry About the K65R Mutation? Similar results have now been described in Malawi, South Africa, and India We know nothing about the relative fitness of the K65R mutation in Subtype C compared to SubtypeB Will K65R be sexually transmitted? Why are we still using d4t in resourcelimited settings?
24 RESULTATS : Sous-types VIH prédominants à baseline, provenant des 28 pays de l étude CASTLE 18 sous-types VIH : A, A/C, A/H, A/K, A1, AE, AG, B, BC, BF, C, CD, Complex, D, F, F1, F2, G SOUSTYPE ATV/r n = 434 n (%) LPV/r n = 431 n (%) TOTAL* n = 865 n (%) AE 28 (6) 28 (6) 56 (6) B 291 (67) 283 (66) 574 (66) BF 27 (6) 38 (9) 65 (8) C 73 ( 17) 65 (15) 138 (16) *Total incluant seulement les sous-types prédominants 6
25 Substitutions IP IAS-USA à baseline par sous-types VIH Soustype B ATV/r n = 291 LPV/r n = 282 >10% I13, D60 L10, I13, D60 >20% L10, M36, I62, I64, A71, V77, I93 M36, I62, I64, A71, V77, I93 >50% L63 L63 >90% Soustype BF ATV/r n = 27 LPV/r n = 38 >10% I13, G16, V77 G16, D60, I64, V77 >20% K20, D60, I62, L63, I93 L10, L63 >50% -- I93 >90% M36 M36 Soustype AE ATV/r n = 27 LPV/r n = 28 >10% G16, I62,V77 L10, I62, V77 >20% L10, K20, L63 G16, K20 >50% I13 I13 >90% M36, H69 M36, H69 Soustype C ATV/r n = 73 LPV/r n = 64 >10% I13, V82 D60, I62, V77 >20% K20, L63 K20, L63 >50% >90% M36, H69, I93 M36, H69, I93 Les substitutions IP multiples classées mineures par la classification IAS-USA (positions d acides aminés listées ci-dessus) surviennent naturellement à baseline chez plusieurs soustypes VIH chez les patients naïfs d IP. La fréquence de certaines substitutions IP à baseline varie largement selon les soustypes: L63 > 50% chez soustype B, <30% chez AE, BF, C. M36 > 90%, chez soustype BF vs. <30% chez soustype B. H69, M36 >90% chez soustype AE vs. <1%, <30% chez soustype B respectivement M36, I93 > 90% chez soustype C vs. < 30% chez soustype B. 10
26 ATV/r North America corrected from poster which stated 47/67; ATV/r AE corrected from poster which stated 22/28 12 Réponse à la semaine 48 selon la région et le soustype VIH : CV<50c/mL Région ATV/r n/n (%) LPV/r n/n (%) Soustype ATV/r n/n (%) LPV/r n/n (%) AFRIQUE 47/67 (70) 52/65 (80) ASIE 32/39 (82) 36/40 (90) EUROPE 53/65 (82) 49/66 (74) AMERIQUE DU NORD AMERIQUE DU SUD 46/67 (69) 50/69 (72) 165/202 (82) 151/203 (74) B 230/291 (79) Non-B 107/143 (75) 210/283 (74) 121/148 (82) AE 23/28 (82) 25/28 (89) BF 21/27 (78) 31/38 (82) C 51/73 (70) 52/65 (80) AUTRE 12/15 (80) 13/17 (76)
27 Summary NNRTIs that are now approved for use in first-line therapy may be more fragile than some long-term clinical trials may suggest. It is only logical that the transmission of NNRTI mutations will continue to increase in settings in which NNRTIs have been used extensively in firstclass therapy. This problem is further exacerbated by data on clustering of NNRTI mutations in new transmissions, which reflects the high fitness of viruses that carry NNRTI mutations.
28 Quebec PHI Study Group Actuel R. Thomas, B Trottier, F Asselin, M Boissonnault, L Charest, H Dion, S Lavoie, D Legault, D Longpré, PJ Maziade, ME Morin, D Murphy, VK Nguyen, R O Brien, S Vézina Clinique Médicale Quartier Latin J-G Baril, P Côté, MA Charron, S Dufresne, MS Joyal P Junod, F Laplante, B Lessard, Y Parent, D Poirier, É Sasseville, A Talbot, D Tessier McGill University Health Centres R Lalonde, J Allen, N Gilmore, M Klein, J MacLeod, M Potter, JP Routy, G Smith; C Tsoukas, J Cox, J Falutz; A Dascal, M Munoz; R Leblanc Centre Hospitalier de l Université de Montréal D Rouleau, C Tremblay, J Bruneau, MA Charron, C Fortin, C Tremblay, A de Pokomandy, A Tabot; N Lapointe Bluma Brenner Daniela Moisi Michel Roger Jean Pierre Routy Hugues Charest Joseph Cox Jean-Guy Baril PHI Cohort Participants CIHR
HIV Drug Resistance: Implications for Prevention and Therapy Mark A. Wainberg McGill University AIDS Centre Montreal, Quebec, Canada Infidelity is one of the most important problems that confront America
TREATMENT FAILURE AND PATTERNS OF GENOTYPIC DRUG RESISTANCE MUTATIONS AMONG HAART EXPERIENCED HIV-1 PATIENTS AT KCMC Theonest Ndyetabura KILIMANJARO CHRISTIAN MEDICAL CENTRE / KILIMANJARO CLINICAL RESERCH
HIV Drug resistanceimplications for therapy Deenan Pillay Africa Centre for Health and Population Studies, UKZN University College London Potential implications of HAART without virological monitoring:
Antiretroviral therapy for HIV infection in infants and children: Towards universal access Executive summary of recommendations Preliminary version for program planning 2010 Executive summary Tremendous
Protease Inhibitor Resistance at 2nd-line HIV Treatment Failure in Sub-Saharan Africa T. Sonia Boender; Raph L. Hamers; Pascale Ondoa; Maureen Wellington; Cleophas Chimbetete; Margaret Siwale; Eman E F
Switch to Dolutegravir plus Rilpivirine dual therapy in cart-experienced Subjects: an Italian cohort Gaetana Sterrantino Azienda Ospedaliero-Universitaria Careggi Infectious diseases, Florence, Italy Background
Paediatric HIV Drug Resistance in African Settings Dr Cissy Kityo Mutuluuza INTEREST Meeting May 5-9, 2014 Lusaka, Zambia Background: ART for children in sub- Saharan Africa 2.3 million children with HIV
HIV Drug Resistance in the Asia- Pacific David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia HIVDR in Asia Pacific Transmitted resistance
Low level viremia and HIV-1 drug resistance in patients with virological rebound after suppression with a first line antiretroviral regimen Manuela Colafigli Catholic University of S. Heart Rome, Italy
Combination Anti-Retroviral Therapy (CART) - Rationale and Recommendation M Dinaker INTRODUCTION The wide availability of effective, safe and mostly well tolerated combined anti-retroviral therapy (CART)
1 Lessons from the Stanford HIV Drug Resistance Database Bob Shafer, MD Department of Medicine and by Courtesy Pathology (Infectious Diseases) Stanford University Outline 2 Goals and rationale for HIVDB
HEPATITIS WEB STUDY Acute C Virus Infection: Epidemiology, Clinical Features, and Diagnosis H. Nina Kim, MD Assistant Professor of Medicine Division of Infectious Diseases University of Washington School
èmes journées du Site ANRS-Cameroun Yaoundé, -4 juin 201 ANRS-122 Le sang total séché sur papier filtre, DBS (Dried Blood Spot), est-il utilisable pour le suivi virologique en routine des patients VIH+
Paediatric HIV treatment update James Nuttall Red Cross War Memorial Children s Hospital & University of Cape Town ART Resistance & New Treatment Options 6 th FIDSSA Conference, 5-7 November 2015 ART Eligibility
HIV DRUG RESISTANCE EARLY WARNING INDICATORS World Health Organization indicators to monitor HIV drug resistance prevention at antiretroviral treatment sites June 2010 Update ACKNOWLEDGEMENTS The preparation
Clinical rationale for viral load testing Francois Venter Wits Reproductive Health & HIV Institute Caveats I m a believer in VLs My talk looks at resource poor environments Why do we need a rationale???
HBV screening and management in HIV-infected children and adolescents Linda Aurpibul M.D. Research Institute for Health Sciences, Chiang Mai University 8% HIV and Hepatitis B Co-infection Among Perinatally
Second Silibinin Workshop, Cologne, 23 rd May 2014 Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C coinfected patients Dominique L Braun, MD Division of
Chapter 3 South African guidelines and introduction to clinical cases 3.1. South African national antiretroviral guidelines When this book was published in 2012 the current national antiretroviral treatment
Prevention of Mother to Child Transmission (MTCT) of HIV Tim Farley Department of Reproductive Health and Research World Health Organization Geneva 17 September 2001 Postgraduate Course in Reproductive
Safety and Efficacy of DAA + PR in HCV/HIV co-infected patients Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA Liver disease is the second leading cause of death amongst HIV-positive
FARMACI, INNOVAZIONE e INFEZIONE DA HIV / AIDS Stefano Vella Dipartimento del Farmaco Istituto Superiore di Sanità - Roma Stages of HIV-1 Life Cycle Targeted by Anti-HIV Drugs In: Gulick RM, Topics HIV
The studies reported in this thesis were performed at the department of Viroscience of the Erasmus Medical Center, Rotterdam, the Netherlands. This research was supported by the Aids Fonds, Netherlands
TB conference, 10-13 June 2014, Durban, South Africa Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection Dr Augustin Ntilivamunda Objectives of 2013 WHO
19 th Annual Conference of the British HIV Association (BHIVA) Dr David Chadwick James Cook University Hospital, Middlesbrough 16-19 April 2013, Manchester Central Convention Complex Occult hepatitis B/HIV
6 th Workshop on HIV Transmission Rome July 2011 HIV-1 mother-to-child transmission and prevention: success and controversies Gabriella Scarlatti San Raffaele Scientific Institute, Milan, Italy Transmission
funding for programmes to prevent HIV drug resistance Call for proposals July 2012 Page 1 van 10 firstname.lastname@example.org Documentnumber 20120719/JKA/RAP Universal Access Lifting barriers to universal access
Population Pharmacokinetics of Atazanavir in Naïve HIV Infected Patients using Medication Events Monitoring System (MEMS) for drug intake timing ANRS -COPHAR clinical trial Céline Verstuyft Pharmacologie,
Challenges of TB in the HIVinfected child CORE Group SOTA Douglas Watson, M.D. University of Maryland, Baltimore 6 October 2009 Challenges of TB in the HIVinfected child Epidemiology: Common, but incidence
Generic antiretrovirals in Europe: a blessing or a curse? Ricardo Jorge Camacho 1 Molecular Biology Laboratory, Centro Hospitalar de Lisboa Ocidental 2 Instituto de Higiene e Medicina Tropical, Universidade
Christoph Boesecke, Patrick Ingiliz, Hans-Jürgen Stellbrink, Mark Nelson, Sanjay Bhagani, Marguerite Guiguet, Marc-Antoine Valantin, Thomas Reiberger, Martin Vogel, Jürgen K. Rockstroh, and the NEAT study
CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) email@example.com The Basics of Drug Resistance: QUESTIONS AND ANSWERS HIV Drug Resistance and ARV-Based Prevention 1. What is drug resistance?
L hépatite virale C en Médecine Familiale- Rurale Montréal-Québec Mai 2015 Demographics Luis Rivero Pinelo MD LMCC, CCFP, FCFP, Fellow SRPC, CSPQ Shawville- Québec Aux États Unis, la prévalence est présente
TUPE089 Virologic suppression outcomes of second-line antiretroviral therapy in a Nigerian cohort. Authors: Adedotun A. Adetunji 1, MBChB, MSc; Chad Achenbach 2, MD, MPH; Joseph Feinglass 3, PhD; Kristin
HIV/Hepatitis C co-infection Update on treatment Eoin Feeney HIV/Hepatitis C coinfection Where we are now Current treatment regimens and outcomes What s coming soon Direct acting antivirals (DAAs) What
Paediatric ARV Procurement Working Group and Coordinated Procurement Product Optimization around the IATT optimized formulations and supporting new product introductions Discussion Points Switch to optimal
Molecular Diagnosis of Hepatitis B and Hepatitis D infections Acute infection Detection of HBsAg in serum is a fundamental diagnostic marker of HBV infection HBsAg shows a strong correlation with HBV replication
Hepatitis B and C Co-infection Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS Objectives Review natural history of hepatitis coinfection Brief overview of treatment indications for
M42-Determinants M19 of HIV Sustained Viral Suppression in HIV/HCV-Coinfected Patients: role of the HCV sustained viral suppression F. Bani-Sadr 1-2, M-A Loko 2, E. Pambrun 2, M. Winnock 2, P. Carrieri
SURVEILLANCE OF INITIAL DRUG RESISTANT HIV-1 AMONG CHILDREN UNDER 18 MONTHS OF AGE NEWLY DIAGNOSED WITH HIV SURVEY REPORT AIDS & TB UNIT Ministry Of Health And Child Welfare Zimbabwe December 2012 1 Table
Medical Journal of Therapeutics Africa 2007 Vol 1, No 2 Page 148 SUMMARY OF GUIDELINES FOR THE USE OF ANTIRETROVIRAL AGENTS IN HIV-INFECTED ADULTS AND ADOLESCENTS. MM Thorell PhD University of the Sciences
Management of HIV/HCV Co-infected Patients David Wyles, MD Associate Professor of Medicine Division of Infectious Diseases University of California, San Diego San Diego, California Disclosures Grants/Research
NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS FOR SEXUAL ASSAULT SURVIVORS Carl LeBuhn, MD Post-Exposure Prophylaxis (PEP) The use of therapeutic agents to prevent infection following exposure to a pathogen
Prevention of Mother-to to-child Transmission of HIV John Kinuthia MBChB, MMed,, MPH Kenyatta National Hospital/University of Nairobi 4 th INTEREST Workshop, Maputo, Mozambique Outline Burden of disease
1 2 HIV testing can be confusing as new tests are being introduced frequently. 3 BCCDC has created the above resource for HIV laboratory testing that are conducted by the Provincial (PHSA) laboratories.
Full-fledged work is in progress towards construction and cloning of codon optimized envelope with subsequent aims towards immunization of mice to study immune responses. 1 2 4 5 6 Figure 4.1: Gel picture
r 2006 British HIV Association HIV Medicine (2006), 7, 487 503 British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006) B Gazzard on behalf
Routine HIV Monitoring Guideline of the HIV/AIDS Division at San Francisco General Hospital Statement of Guideline: Patients will be routinely evaluated and monitored for HIV parameters, antiretroviral
Le Colloque Européen et International THS Biarritz,11 au 14 octobre 2011 NOUVELLE PRÉOCCUPATION CONCERNANT LA TRANSMISSION DU VIRUS DE L HÉPATITE C CHEZ LES USAGERS DE DROGUES INJECTABLES À MONTRÉAL, CANADA
HIV Diagnosis HIV Diagnosis and Pathogenesis Scott M. Hammer, M.D. Consider in anyone presenting with symptoms and signs compatible with an HIV-related syndrome or in an asymptomatic person with a risk
SIT Graduate Institute/SIT Study Abroad SIT Digital Collections Independent Study Project (ISP) Collection SIT Study Abroad Fall 12-1-2014 HIV Drug Resistance Among Infants and Children in South Africa:
French policy on access to care for illegal immigrants living with HIV: Michel CELSE 1, Laurent GEFFROY 1, Pierre-Yves GEOFFARD 1, Patrick YENI 1, Commission on migrants of the French National AIDS Council
Poster # 42 Resistance in PBMCs Can Predict Virological Rebound after Therapy Switch in cart- Treated Patients with Undetectable HIV-RNA D Armenia 1, M Zaccarelli 2, V Borghi 3, W Gennari 3, A Giannetti
UPDATE IN HIV POST-EXPOSURE PROPHYLAXIS Weerawat Manosuthi Outline Case scenario of postexposure prophylaxis Risks of and how to manage postexposure prophylaxis Current PEP guideline US PHS 2013 New York
Didactic Series Updated Post-Exposure Prophylaxis (PEP) Guidelines Daniel Lee, MD UCSD Medical Center, Owen Clinic January 9, 2014 ACCREDITATION STATEMENT: University of California, San Diego School of
Post AASLD Update in HCV Torino, 10 Gennaio 2013 Fattori che possono influenzare il trattamento: RVR e Lead in Alessia Ciancio Università di Torino Città della Salute e delle Scienze Will predictors usefull
Options for Doing Cost-Effectiveness Analysis Decision Analysis Example after Occupational Exposure to Clinical trial Mathematical modeling Clinical Trial Incremental Cost-Effectiveness Ratio Conduct a
Current State of AIDS Epidemic in Nigeria: Role of ARVs on PMTCT Atiene Solomon SAGAY MD, FWACS, FRCOG (Lond) Professor of Obstetrics and Gynaecology Chairman, PMTCT National Task Team 1 OUTLINE Introduction
SURVEILLANCE OF TRANSMITTED HIV DRUG RESISTANCE AMONG VOLUNTARY COUNSELING AND TESTING CENTERS IN GONDAR TOWN ETHIOPIA ETHIOPIAN PUBLIC HEALTH INSTITUTE 2014 PREFACE Ethiopia has been progressively expanding
143 Chapter 10 Human Immuno Deficiency Virus Infection Chapter 10 Human Immuno Deficiency Virus Infection...143 HIV infection...144 Clinical Features...146 Clinical Staging of HIV infection recommended
Antiretroviral Therapy Adult ART Table 1. When to Start Therapy* Clinical Category CD4+ Count Viral Load Recommendation Symptomatic (AIDS or severe symptoms) Any value Any value Treat Asymptomatic, AIDS
ACCESS TO AFFORDABLE TREATMENT FOR HIV/AIDS: THE ISSUES AIDS Law Unit Legal Assistance Centre July, 2002 INTRODUCTION Although there is currently no cure for HIV/Aids, treatment has, however, been developed
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
Antiretroviral Treatment Michael A. Tolle, MD, MPH Heidi Schwarzwald, MD, MPH Nancy R. Calles, MSN, PNP, ACRN, MPH Objectives 1. Discuss the goals of treatment for human immunodeficiency virus (HIV) infection.
Acute Hepatitis C A short-term illness that usually occurs within the first six months after someone is exposed to the hepatitis C virus (HCV). 1 Antibodies Proteins produced as part of the body s immune
Julius Bustamante, Pajaros Artwork from Hospital Audiences, Inc. (HAI), a nonprofit organization that inspires healing, growth and learning through access to the arts for the culturally underserved. Janssen
HIV/AIDS Prevention and Care Nancy S. Padian, PhD, MPH Professor, Obstetrics, Gynecology & Reproductive Sciences Associate Director for Research, Global Health Sciences and AIDS Research Institute: University
HIV Dr Leon Levin Head - Paediatric HIV Treatment Programmes Right to Care Disclaimer This talk represents my personal experience in managing teenagers with HIV over the last 14 years. It does not purport
21 st Annual Conference of the British HIV Association (BHIVA) Dr Andrew Hill University of Liverpool 21-24 April 2015, The Brighton Centre 21 st Annual Conference of the British HIV Association (BHIVA)
POSTEXPOSURE PROPHYLAXIS Bloodborne viruses Hepatitis B Hepatitis C HIV Hepatitis B Risk of seroconversion HBeAg negative 2% HBeAg positive 20-40% If seroconvert most recover completely and develop immunity
HIV Guidelines. New Strategies. Santiago Moreno Hospital Universitario Ramón y Cajal Madrid HIV Guidelines. New Strategies. Outline HIV Guidelines What is new? New strategies Treatment as Prevention HIV
DOI: 10.1111/hiv.12217. ORIGINAL RESEARCH Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult
ARV treatment Update 2012 Avondseminarie 18 december 2012 Eric Florence ITG, Antwerpen Three big conferences in 2012 http://retroconference.org/2012/ http://www.aids2012.org/ http://www.hiv11.com/ Current
STOP HIV/AIDS Pilot Project INDICATORS QUARTERLY REPORT: 1 October through 31 December SUBMITTED TO: The BC Ministry of Health Services SUBMITTED BY: Dr. Rolando Barrios, Dr. Mark Gilbert, Dr. Kate Health,
A 12-22 Month Follow-Up of HIV Patients Whose Therapy Was Optimized by Using HIV Genotyping Cynthia J. Carlyn, MD * Aldona L. Baltch, MD * Marty H. St. Clair, BS Mary J. George, PhD * Raymond P. Smith,
Hepatitis C Vaccines: Are we making progress? Second International Hepatitis Cure and Eradication Meeting. Vancouver November, 2015 Objectives: Review the need for a preventive vaccine in 2015. Identify
WHO/HIVRESNET HIV DRUG RESISTANCE LABORATORY STRATEGY JULY, 2010 1 Table of Contents Abbreviations... 4 1. WHO/HIVResNet Global HIV Drug Resistance Strategy... 5 1.1. NATIONAL HIVDR WORKING GROUP...6 1.2.
HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain Yes, still too many Measures to eradicate an Infectious Disease Prevention: Vaccination Screening
Chapter 36 Media Directory Drugs for Viral Infections Slide 23 Slide 27 Slide 29 Zidovudine Animation Saquinavir Mesylate Animation Acyclovir Animation Upper Saddle River, New Jersey 07458 All rights reserved.
Le nuove sfide dell HIV Caso clinico Un paziente altoviremico Giuseppina Liuzzi Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani Caso clinico(1) In data 29.10.15 Donna in gravidanza 19a
HIV/AIDS Care: The Diagnosis Code Series 2 Prepared By: Stacey L. Murphy, MPA, RHIA, CPC AHIMA Approved ICD-10-CM/ICD-10-CM Trainer Learning Outcomes Identify and explain the difference between ICD-9-CM
Your consent to our cookies if you continue to use this website.